| 2024-12-19 | +60.7% | legal | SEC EDGAR | PSNL 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-12-19 | +60.7% | news | Business Wire | Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Business Wire |
| 2024-12-19 | +60.7% | M&A | Mugglehead Investment Magazine | Personalis Inc share price jumps 50% on deals with Merck and Moderna - Mugglehead Investment Magazine |
| 2025-05-07 | +27.9% | earnings | Seeking Alpha | Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth |
| 2025-05-07 | +27.9% | earnings | Seeking Alpha | Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript |
| 2024-11-06 | -26.7% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-08-05 | -21.2% | earnings | Seeking Alpha | Personalis GAAP EPS of -$0.23 beats by $0.01, revenue of $17.2M misses by $2.91M |
| 2025-08-05 | -21.2% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-02-14 | +20.8% | earnings | Seeking Alpha | Exciting Technology At Personalis, But Profitability Eludes Them |
| 2025-08-06 | -20.1% | earnings | Seeking Alpha | Personalis outlines $70M–$80M revenue target for 2025 amid 59% sequential clinical test growth and revised biopharma outlook |
| 2025-08-06 | -20.1% | earnings | Seeking Alpha | Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript |
| 2025-11-10 | +20.0% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2025-11-07 | +18.5% | analyst | Yahoo Finance | Personalis, Inc. (NASDAQ:PSNL) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance |
| 2025-11-07 | +18.5% | earnings | simplywall.st | Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50 - simplywall.st |
| 2025-11-05 | -17.0% | earnings | Seeking Alpha | Personalis narrows 2025 revenue outlook to $68M-$73M amid biopharma project delays and rapid clinical test growth |
| 2025-11-05 | -17.0% | earnings | Seeking Alpha | Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript |
| 2022-10-03 | +16.7% | legal | SEC EDGAR | PSNL 8-K: 1.01 (SEC Filing) |
| 2023-11-28 | -16.7% | legal | SEC EDGAR | PSNL 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-11-04 | -14.0% | earnings | Seeking Alpha | Personalis GAAP EPS of -$0.24 beats by $0.03, revenue of $14.5M beats by $1.19M |
| 2025-11-04 | -14.0% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-05-06 | +14.0% | earnings | Seeking Alpha | Personalis GAAP EPS of -$0.18 beats by $0.07, revenue of $20.6M beats by $3.19M |
| 2025-05-06 | +14.0% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-01-08 | -14.0% | earnings | Seeking Alpha | Personalis expects FY 2025 revenue between $69M and $70M |
| 2026-01-08 | -14.0% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2024-08-16 | +14.0% | legal | SEC EDGAR | PSNL 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2026-02-10 | +14.0% | news | Seeking Alpha | Personalis rises on Medicare coverage for NeXT Personal cancer test |
| 2026-02-10 | +14.0% | news | Benzinga | Why Is Personalis Stock Soaring Tuesday? - Personalis (NASDAQ:PSNL) - Benzinga |
| 2026-02-10 | +14.0% | news | Stock Titan | Medicare to cover blood test that flags returning lung cancer earlier - Stock Titan |
| 2026-02-10 | +14.0% | news | Investing.com Nigeria | Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com - Investing.com Nigeria |
| 2026-02-10 | +14.0% | news | Seeking Alpha | Personalis rises on Medicare coverage for NeXT Personal cancer test - Seeking Alpha |
| 2026-02-10 | +14.0% | news | Stocktwits | Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits |
| 2026-03-12 | -13.4% | news | Business Wire | Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® |
| 2026-03-12 | -13.4% | news | Stock Titan | Ultrasensitive blood test flags 100x higher breast cancer relapse risk - Stock Titan |
| 2023-01-17 | -13.2% | news | Seeking Alpha | Personalis Stock: Looking For A Potential Turnaround In 2023 (PSNL) - Seeking Alpha |
| 2023-04-17 | -13.2% | news | Seeking Alpha | Personalis: Revisiting The Investment Thesis (NASDAQ:PSNL) - Seeking Alpha |
| 2024-01-11 | -12.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-04-22 | +12.3% | news | Yahoo Finance | Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? - Yahoo Finance |
| 2022-12-14 | -11.7% | legal | SEC EDGAR | PSNL 8-K: 5.02 and (SEC Filing) |
| 2025-01-07 | -11.7% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-07-10 | -11.0% | M&A | Seeking Alpha | Personalis expands Tempus deal to include colorectal cancer testing |
| 2026-02-26 | +10.1% | earnings | Seeking Alpha | Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M |
| 2026-02-26 | +10.1% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +10.1% | earnings | Yahoo Finance | Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance |
| 2026-02-26 | +10.1% | earnings | Quiver Quantitative | Progyny Inc. (PGNY) Stock Falls on Q4 2025 Earnings - Quiver Quantitative |
| 2021-08-04 | +10.0% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2023-11-07 | +10.0% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2022-11-16 | -10.0% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2025-11-28 | -9.8% | news | Seeking Alpha | Personalis: A Growth Inflection Is Imminent, Hold |
| 2025-11-28 | -9.8% | legal | SEC EDGAR | PSNL 8-K: 8.01 and (SEC Filing) |
| 2025-11-28 | -9.8% | news | simplywall.st | Insiders Of Personalis Make A Tidy Sum Selling At US$7.14 - simplywall.st |
| 2023-01-04 | +9.3% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2022-08-03 | +9.1% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | +8.8% | news | Business Wire | Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 |
| 2026-04-13 | +8.8% | news | Stock Titan | Personalis adds a blood-test feature to track cancer drug resistance - Stock Titan |
| 2026-02-25 | +8.6% | earnings | Seeking Alpha | Personalis Q4 2025 Earnings Preview |
| 2022-02-24 | +8.5% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-01-23 | -8.5% | executive | Investing.com | Personalis CFO Tachibana sells $13,811 in shares - Investing.com |
| 2024-10-28 | +8.4% | news | Seeking Alpha | The Proper Play On Personalis (NASDAQ:PSNL) - Seeking Alpha |
| 2025-11-03 | -8.4% | earnings | Seeking Alpha | Personalis Q3 2025 Earnings Preview |
| 2026-01-12 | +8.4% | news | Stock Titan | New blood test add-on spots cancer resistance mutations in real time - Stock Titan |
| 2023-06-14 | -8.3% | legal | SEC EDGAR | PSNL 8-K: 5.02 (SEC Filing) |
| 2026-01-07 | -8.1% | news | simplywall.st | Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st |
| 2024-01-05 | +7.9% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-09-11 | +7.7% | news | Seeking Alpha | Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges |
| 2025-09-11 | +7.7% | news | Seeking Alpha | Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges - Seeking Alpha |
| 2025-02-27 | -7.5% | news | Seeking Alpha | Personalis files to sell 14.04M shares of common stock for holders |
| 2025-02-27 | -7.5% | earnings | Seeking Alpha | Personalis GAAP EPS of -$0.23 beats by $0.05, revenue of $16.8M beats by $1.33M |
| 2025-02-27 | -7.5% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-04-06 | -6.7% | analyst | Cổng thông tin điện tử tỉnh Tây Ninh | Is Personalis (PSNL) Stock Risky Now | Price at $6.61, Up 0.46% - Analyst Upgrade - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2023-02-23 | -6.7% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2022-05-04 | -6.6% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2023-08-28 | +6.6% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2023-08-15 | -6.6% | analyst | TradingView | PSNL Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-01-30 | -6.4% | earnings | DirectorsTalk Interviews | Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews |
| 2026-04-07 | -6.4% | earnings | MarketBeat | Personalis (NASDAQ:PSNL) Stock Price Down 8.4% - Here's What Happened - MarketBeat |
| 2023-05-03 | +5.9% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2023-08-08 | +5.8% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2022-02-10 | -5.8% | analyst | eToro | PSNL Stock Price | Analyst Target 12.00 & Consensus - eToro |
| 2025-11-25 | +5.7% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2022-03-25 | -5.6% | legal | SEC EDGAR | PSNL 8-K: 5.02 and (SEC Filing) |
| 2024-08-07 | +5.6% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2023-12-05 | -5.3% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2026-03-16 | +4.7% | news | Seeking Alpha | Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL |
| 2022-09-05 | -4.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Personalis (PSNL) - Zacks Investment Research |
| 2025-09-03 | +4.4% | news | Seeking Alpha | Personalis reports data from lung cancer trial |
| 2026-04-08 | -4.4% | news | Stock Titan | T. Rowe Price lists 4.5% stake in Personalalis (NASDAQ: PSNL) - Stock Titan |
| 2022-01-06 | +4.1% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2022-01-03 | -3.9% | legal | SEC EDGAR | PSNL 8-K: 1.01 and (SEC Filing) |
| 2024-05-08 | +3.8% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -3.7% | news | Business Wire | Personalis to Announce First Quarter 2026 Financial Results |
| 2026-04-23 | -3.7% | earnings | Stock Titan | Personalis schedules May 7 webcast and call for Q1 2026 results - Stock Titan |
| 2026-03-17 | +3.6% | executive | Business Wire | Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption |
| 2026-03-17 | +3.6% | legal | SEC EDGAR | PSNL 8-K: 5.02 (SEC Filing) |
| 2026-03-17 | +3.6% | executive | Stock Titan | Personalis (PSNL) CFO granted 206,250 options and 34,375 RSUs - Stock Titan |
| 2026-03-17 | +3.6% | news | Stock Titan | Personalis taps MRD lead Richard Chen as president to advance cancer detection - Stock Titan |
| 2025-08-04 | +3.6% | earnings | Seeking Alpha | Personalis Q2 2025 Earnings Preview |
| 2025-06-08 | +3.6% | news | Seeking Alpha | Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks |
| 2025-06-08 | +3.6% | news | Seeking Alpha | Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha |
| 2026-03-02 | -3.5% | news | Motley Fool | Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK) |
| 2024-02-28 | +3.1% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-01-10 | -3.1% | M&A | GuruFocus | Catherine Wood's Strategic Acquisition of Personalis Inc Shares - GuruFocus |
| 2026-01-17 | -3.0% | news | simplywall.st | Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st |
| 2025-05-04 | +3.0% | news | Intellectia AI | PSNL Forecast — Price Prediction for 2026. Should I Buy PSNL? - Intellectia AI |
| 2025-02-28 | -2.8% | earnings | Seeking Alpha | Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript |
| 2024-09-19 | +2.8% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2026-04-01 | +2.5% | news | Business Wire | Personalis to Participate in the 25th Annual Needham Virtual Conference |
| 2026-04-01 | +2.5% | news | Stock Titan | Personalis executives to appear at Needham virtual conference Apr. 15 - Stock Titan |
| 2026-04-01 | +2.5% | news | Cổng thông tin điện tử tỉnh Tây Ninh | PSNL Stock Analysis: Personalis Inc. gains 4.24 pct, holds 6.64 dollar level - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-12-27 | -2.5% | legal | SEC EDGAR | PSNL 8-K: 8.01 and (SEC Filing) |
| 2025-05-05 | -2.4% | earnings | Seeking Alpha | Personalis Q1 2025 Earnings Preview |
| 2022-11-02 | +2.1% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2026-02-13 | +1.9% | legal | DirectorsTalk Interviews | Personalis, Inc. (PSNL) Stock Analysis: Evaluating a 34.51% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews |
| 2026-02-13 | +1.9% | M&A | TradingView | Tempus Ai Acquires Over 320K Shares of Personalis - TradingView |
| 2021-11-04 | +1.8% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2025-02-26 | +1.8% | earnings | Seeking Alpha | Personalis Q4 2024 Earnings Preview |
| 2025-10-30 | +1.7% | news | simplywall.st | Institutional investors have a lot riding on Personalis, Inc. (NASDAQ:PSNL) with 42% ownership - simplywall.st |
| 2023-03-08 | +1.7% | legal | SEC EDGAR | PSNL 8-K: 5.02 and (SEC Filing) |
| 2021-09-15 | -1.5% | news | The Motley Fool | Personalis - PSNL - Stock Price & News - The Motley Fool |
| 2025-04-24 | +1.5% | news | Stock Titan | PSNL Stock Price, News & Analysis | Personalis - Stock Titan |
| 2026-02-02 | -1.5% | news | Yahoo Finance | Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance |
| 2026-02-02 | -1.5% | news | Stock Titan | Blood test spots cancer progression 161 days before scans in study - Stock Titan |
| 2021-05-05 | -1.4% | legal | SEC EDGAR | PSNL 8-K: 2.02 and (SEC Filing) |
| 2024-06-27 | -1.0% | legal | SEC EDGAR | PSNL 8-K: 1.01 and (SEC Filing) |
| 2026-03-24 | +1.0% | analyst | Insider Monkey | Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 |
| 2026-03-24 | +1.0% | analyst | Yahoo Finance | Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 - Yahoo Finance |
| 2026-04-21 | -0.8% | news | Business Wire | Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 |
| 2026-04-21 | -0.8% | news | Stock Titan | This cancer-monitoring test tracked relapse and resistance in 10,000 patients - Stock Titan |
| 2026-02-27 | +0.8% | earnings | Moby | Personalis, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-27 | +0.8% | news | Seeking Alpha | Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate |
| 2026-02-27 | +0.8% | earnings | Seeking Alpha | Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript |
| 2026-02-27 | +0.8% | news | DirectorsTalk Interviews | Personalis, Inc. (PSNL) Stock Analysis: Exploring a Promising 24.98% Upside with Innovative Cancer Genomics - DirectorsTalk Interviews |
| 2026-04-03 | -0.5% | legal | Cổng thông tin điện tử tỉnh Lào Cai | PSNL Stock Analysis: Personalis Inc. Modest Daily Uptick At 6.58 USD Amid Genomics Sector Trends - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-11-27 | -0.5% | news | Seeking Alpha | Personalis: A Growth Inflection Is Imminent, Hold - Seeking Alpha |
| 2021-08-25 | +0.3% | legal | SEC EDGAR | PSNL 8-K: 1.01 and 2.03 (SEC Filing) |
| 2025-08-22 | -0.2% | news | Seeking Alpha | Personalis gains as VA awards work order worth up to $13.5M |
| 2025-08-22 | -0.2% | legal | SEC EDGAR | PSNL 8-K: 8.01 (SEC Filing) |
| 2026-01-16 | -0.2% | news | DirectorsTalk Interviews | Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews |
| 2026-03-01 | -0.1% | news | Motley Fool | Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares |
| 2025-08-10 | -0.0% | analyst | simplywall.st | These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat - simplywall.st |
| 2025-07-09 | -0.0% | legal | SEC EDGAR | PSNL 8-K: 1.01 (SEC Filing) |